Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, China.
Eur J Cancer. 2015 Nov;51(17):2587-95. doi: 10.1016/j.ejca.2015.08.006. Epub 2015 Aug 26.
To evaluate the survival benefit of intensity-modulated radiotherapy (IMRT) compared with conventional two-dimensional radiotherapy (2D-CRT) in nasopharyngeal carcinoma (NPC) using a large cohort with long follow-up.
We retrospectively analysed 7081 non-metastatic NPC patients who received curative IMRT or 2D-CRT from February 2002 to December 2011.
Of the 7081 patients, 2245 (31.7%) were administered IMRT, while 4836 (68.3%) were administered 2D-CRT. At 5 years, the patients administered IMRT had significantly higher local relapse-free survival (LRFS), loco-regional relapse-free survival (LRRFS), progression-free survival (PFS) and overall survival (OS) (95.6%, 92.5%, 82.1% and 87.4%, respectively) than those administered 2D-CRT (90.8%, 88.5%, 76.7% and 84.5%, respectively; p<0.001). The distant metastasis-free survival (DMFS) was higher for IMRT than 2D-CRT, with borderline significance (87.6% and 85.7%, respectively; p=0.056). However, no difference was observed between IMRT and 2D-CRT in nodal relapse-free survival (NRFS; 96.3% and 97.4%, respectively; p=0.217). Multivariate analyses showed that IMRT was an independent protective prognostic factor for LRFS, LRRFS and PFS, but not NRFS, DMFS or OS.
IMRT provided an improved LRFS, LRRFS and PFS in both the early and advanced T classifications and overall stage for non-disseminated NPC compared with 2D-CRT. However, no significant advantage was observed in NRFS, DMFS or OS when IMRT was used.
本研究旨在通过对大样本、长期随访的病例进行分析,评估调强放疗(IMRT)对比常规二维放疗(2D-CRT)在鼻咽癌(NPC)患者中的生存获益。
回顾性分析了 2002 年 2 月至 2011 年 12 月期间接受根治性 IMRT 或 2D-CRT 治疗的 7081 例非转移性 NPC 患者。
7081 例患者中,2245 例(31.7%)接受了 IMRT,4836 例(68.3%)接受了 2D-CRT。5 年时,接受 IMRT 的患者局部无复发生存率(LRFS)、局部区域无复发生存率(LRRFS)、无进展生存率(PFS)和总生存率(OS)显著高于接受 2D-CRT 的患者(95.6%、92.5%、82.1%和 87.4%,分别;p<0.001)。虽然远处无转移生存率(DMFS)也有提高的趋势,但两组之间无显著差异(87.6%和 85.7%,分别;p=0.056)。此外,两组间无复发生存率(NRFS)无显著差异(96.3%和 97.4%,分别;p=0.217)。多因素分析显示,IMRT 是 LRFS、LRRFS 和 PFS 的独立保护预后因素,但不是 NRFS、DMFS 或 OS 的独立保护预后因素。
与 2D-CRT 相比,IMRT 可为未发生远处转移的 NPC 患者提供更优的 LRFS、LRRFS 和 PFS,无论肿瘤处于早期还是晚期 T 分期,整体分期如何。然而,在 NRFS、DMFS 或 OS 方面,IMRT 并未显示出明显优势。